Impax Laboratories Inc. (IPXL) Stock Research, Analysis & News
Quick Analysis on Impax Laboratories Inc. (IPXL) Stock as of May 18, 2012
 | Previous Closing Price $21.08 is below its 50 day moving average $23.52 |
| Previous Closing Price $21.08 is below its 200 day moving average $21.36 |
| The Price/Earnings To Growth ratio (PEG) is less than 1 |
 | The Stock pays no dividend |
 | The closing price $21.08 is more than 23.34% away from its one year target price of $26.00 |
 | Current Short Ratio 9.10 is great than 1 |
(See more information about Impax Laboratories Inc. (IPXL) Stock below)
Impax Laboratories Inc. (IPXL) Stock Profile Summary
Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates in two divisions, Global Pharmaceuticals and Impax Pharmaceutical. The Global Pharmaceuticals division develops, manufactures, sells, and distributes generic pharmaceutical products. It offers generic pharmaceutical prescription products directly to wholesalers and retail drug chains; and generic pharmaceutical over-the-counter and prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimers disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinsons disease, and schizophrenia. As of February 15, 2010, the company marketed 83 generic pharmaceuticals representing dosage variations of 26 different pharmaceutical compounds through its Global Pharmaceuticals Division, as well as 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements partners. Impax Laboratories markets and sells its generic pharmaceutical prescription drug products in the continental United States and the Commonwealth of Puerto Rico. It has alliance agreements with Teva Pharmaceuticals Curacao N.V., Wyeth, Schering-Plough Corporation, and Putney Inc. The company was founded in 1993 and is headquartered in Hayward, California.
Impax Laboratories Inc. (IPXL) Stock Key Statistics Research and Analysis as of May 18, 2012
| Stock Exchange | NasdaqNM |
| Market Capitalization | $1.371B
|
| Trade Volume (Average Trading Volume) | 367,601 (498,295) |
| Price/Sales | 2.59 |
| Price/Book | 2.20 |
| P/E | 22.45 |
| Earning/Share | $0.939 |
| Current Year EPS Estimate | $1.81 |
| Next Year EPS Estimate | $1.95 |
| Previous Closing Price | $21.08 |
| 50 Day Price Moving Average | $23.52 |
| 200 Day Price Moving Average | $21.36 |
| 1 yr Target Price | $26.00 |
| PEG Ratio | 0.64 |
| Short Ratio | 9.10 |
| EBITDA | $124.0M |
Impax Laboratories Inc. (IPXL) Stock Competitor Research and Analysis
Mutual Funds with Impax Laboratories Inc. (IPXL) Stock in its top 10 holdings
Latest Market News on Impax Laboratories Inc. (IPXL)
Click here to find the latest news on Impax Laboratories Inc. (IPXL)
Looking for Market Opportunties?
Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center
See other companies in the same industry
Mylan, Inc. (MYL) Teva Pharmaceutical Industries Limited (TEVA) Amgen Inc. (AMGN) Biogen Idec Inc. (BIIB) Genzyme Corp. (GENZ) Gilead Sciences Inc. (GILD) Life Technologies Corporation (LIFE) Watson Pharmaceuticals Inc. (WPI) King Pharmaceuticals Inc. (KG) Pfizer Inc. (PFE) Johnson & Johnson (JNJ) GlaxoSmithKline plc (GSK) Sanofi-Aventis (SNY) Novartis AG (NVS) AstraZeneca PLC (AZN)
Research on Impax Laboratories Inc. (IPXL)
